Showing results (21-30 of 42) with videos related to

Sort By:
Pageof 5
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 7, 2010
Epoetin alfa in patients with advanced-stage Hodgkin's lymphoma: results of the randomized placebo-controlled GHSG HD15EPO trialAndreas Engert, Andreas Josting, Heinz Haverkamp, et al.
European Journal of Cancer (Oxford, England : 1990)|February 7, 2025
Phase 2 study of futibatinib in patients with gastric or gastroesophageal junction cancer harboring FGFR2 amplificationsTaroh Satoh, Philippe Barthélémy, Lucia Nogova, et al.
JTO Clinical and Research Reports|March 12, 2026
MET-Driven Resistance to Sotorasib in KRAS G12C-Mutant NSCLC and Response to Combined KRAS and MET InhibitionRichard Riedel, Lea Ruge, Malte Verheyen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 10, 2026
Molecular and clinical characteristics of patients with non-small cell lung cancer (NSCLC) harboring KRAS Q61 mutations to assess therapeutic responsesLea Ruge, Felix John, Malte Verheyen, et al.
Lung Cancer (Amsterdam, Netherlands)|August 14, 2023
Clinicopathologic and molecular characteristics of small-scale ROS1-mutant non-small cell lung cancer (NSCLC) patientsMoritz Glaser, Anna Rasokat, Darinka Prang, et al.
The Lancet. Oncology|August 14, 2019
Rogaratinib in patients with advanced cancers selected by FGFR mRNA expression: a phase 1 dose-escalation and dose-expansion studyMartin Schuler, Byoung Chul Cho, Cyrus Michael Sayehli, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|July 10, 2023
MET Fusions in NSCLC: Clinicopathologic Features and Response to MET InhibitionRichard Riedel, Jana Fassunke, Andreas H Scheel, et al.
Lung Cancer (Amsterdam, Netherlands)|May 4, 2020
Co-occurrence of targetable mutations in Non-small cell lung cancer (NSCLC) patients harboring MAP2K1 mutationsMatthias Scheffler, Alessandra Holzem, Anna Kron, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 23, 2011
Early prediction of nonprogression in advanced non-small-cell lung cancer treated with erlotinib by using [(18)F]fluorodeoxyglucose and [(18)F]fluorothymidine positron emission tomographyThomas Zander, Matthias Scheffler, Lucia Nogova, et al.
Clinical Nuclear Medicine|January 14, 2025
The Value of Multidisciplinary Neuro-oncological Tumor Boards to Increase the Accuracy of FET PET for Identifying Brain Tumor RelapseGarry S Ceccon, Jan-Michael Werner, Maximilian I Ruge, et al.
Pageof 5